ACE inhibitor therapy can often improve renal blood flow (RBF) and sodium excretion rates in congestive heart failure (CHF) and slow down the progression of chronic renal disease, but it can also cause a syndrome of “functional renal insufficiency” and/or hyperkalemia. Here, ACE is linked to chronic kidney disease.